KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Non Operating Income (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Non Operating Income for 7 consecutive years, with -$229.1 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 10368.11% to -$229.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$216.7 million through Dec 2025, down 14081.74% year-over-year, with the annual reading at -$235.3 million for FY2025, 15300.92% down from the prior year.
  • Non Operating Income hit -$229.1 million in Q4 2025 for Royalty Pharma, down from $17.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $113.8 million in Q2 2022 to a low of -$229.1 million in Q4 2025.
  • Historically, Non Operating Income has averaged -$12.9 million across 5 years, with a median of -$2.0 million in 2022.
  • Biggest five-year swings in Non Operating Income: soared 106459.81% in 2022 and later tumbled 10628.33% in 2023.
  • Year by year, Non Operating Income stood at -$4.8 million in 2021, then surged by 75.83% to -$1.2 million in 2022, then crashed by 10628.33% to -$125.0 million in 2023, then surged by 98.25% to -$2.2 million in 2024, then crashed by 10368.11% to -$229.1 million in 2025.
  • Business Quant data shows Non Operating Income for RPRX at -$229.1 million in Q4 2025, $17.1 million in Q3 2025, and -$1.5 million in Q2 2025.